Navigation Links
Gen-Probe Reports Strong Financial Results for First Quarter 2008, Raises Full-Year Guidance
Date:4/28/2008

r our industrial collaborations, may not proceed as planned, (v) the risk that products including our PROCLEIX ULTRIO assay for blood screening may not be approved by regulatory authorities or commercially available in the time frame we anticipate, or at all, (vi) we may not be able to compete effectively, (vii) we may not be able to maintain our current corporate collaborations and enter into new corporate collaborations or customer contracts, (viii) we are dependent on Novartis, Siemens (as assignee of Bayer) and other third parties for the distribution of some of our products, (ix) we are dependent on a small number of customers, contract manufacturers and single source suppliers of raw materials, (x) changes in third-party reimbursement policies regarding our products could adversely affect sales of our products, (xi) changes in government regulation affecting our diagnostic products could harm our sales and increase our development costs, (xii) the risk that our intellectual property may be infringed by third parties or invalidated, and (xiii) our involvement in patent and other intellectual property and commercial litigation could be expensive and could divert management's attention. The foregoing list sets forth some, but not all, of the factors that could affect our ability to achieve results described in any forward-looking statements. For additional information about risks and uncertainties we face and a discussion of our financial statements and footnotes, see documents we file with the SEC, including our most recent annual report on Form 10-K and all subsequent periodic reports. We assume no obligation and expressly disclaim any duty to update forward-looking statements to reflect events or circumstances after the date of this news release or to reflect the occurrence of subsequent events.

Contact:

Michael Watts

Sr. director, investor relations and corporate communications

858-410-8673


'/>"/>

SOURCE Gen-Probe Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related biology technology :

1. Gen-Probe to Webcast Presentation at Morgan Stanley Global Healthcare Unplugged Conference
2. Gen-Probe to Webcast Presentations at Lehman and Cowen Healthcare Conferences
3. Gen-Probe Reports Strong Financial Results for Fourth Quarter and Full Year 2007
4. Carl Hull Named President and Chief Operating Officer of Gen-Probe
5. Gen-Probe Announces Webcast of Fourth Quarter and Full Year 2007 Earnings Conference Call
6. Gen-Probe to Webcast Three Upcoming Presentations
7. Gen-Probe Reports Strong Financial Results for Third Quarter 2007, Raises Full-Year Guidance for Earnings Per Share and Total Revenues
8. Gen-Probe to Webcast Presentation at Bank of Americas 37th Annual Investment Conference
9. Simcere Pharmaceutical Group Reports Proposed Private Sale of Ordinary Shares by Existing Shareholder
10. CV Therapeutics Reports 2008 First Quarter Financial Results
11. Caliper Life Sciences Reports West Coast Consolidation of Operations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... 2015  Pfenex Inc. (NYSE MKT: PFNX), a clinical-stage ... today announced that it will be presenting at CALBIO ... 2 nd at 3pm PST. Patrick Lucy, chief business ... the current state of the biosimilar industry landscape entitled ... For more information on CALBIO 2015 and ...
(Date:2/26/2015)... , Feb. 26, 2015 S&P Capital ... Factual Stock Report coverage on MabVax Therapeutics Holdings Inc ... is a clinical stage biotechnology company focused on the ... medical needs in the treatment of cancer. MabVax has ... on the protective immune responses generated by patients who ...
(Date:2/26/2015)... Calif. , Feb. 26, 2015   Regulus ... biopharmaceutical company leading the discovery and development of innovative ... Xanthopoulos , Ph.D., President and Chief Executive Officer of ... and Company 35 th Annual Healthcare Conference on ... conference is being held at the Boston Marriott Copley ...
(Date:2/26/2015)... , Feb. 26, 2015  NuGene International, Inc. ... products for skin and hair rejuvenation, has announced ... agency of record for investor relations and strategic ... our distribution, sales and diversification strategies – and ... and prospective shareholders," stated Ali Kharazmi CEO of ...
Breaking Biology Technology:S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 2S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 3S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 4S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 5Regulus to Present at Cowen and Company 35th Annual Healthcare Conference 2Regulus to Present at Cowen and Company 35th Annual Healthcare Conference 3NuGene International, Inc. Selects Capital Market Relations for Strategic Investor Relations 2NuGene International, Inc. Selects Capital Market Relations for Strategic Investor Relations 3
... Reiterates $3.00 per Share Proposal is Best and Final ... Company,(NYSE: LLY ) today reaffirmed that its $3.00 ... SGXP ) represents its best and final offer,for the ... two,companies announced the signing of a definitive merger agreement, ...
... Bionovo, Inc.,(Nasdaq: BNVI ), a pharmaceutical company focused ... in the areas of women,s health and,cancer, announced today ... presenting at the BMO Capital Markets 2008 Focus on ... begin at 2:15 PM,ET on Tuesday, August 5, 2008 ...
... to Monitor Activity of New ... Class of Potent Antiretroviral Drugs, SOUTH SAN ... ) today announced the launch of its,PhenoSense(R) Integrase assay, built ... susceptibility of,HIV to a new and potent class of integrase ...
Cached Biology Technology:Lilly Reaffirms Purchase Offer for SGX Pharmaceuticals 2Lilly Reaffirms Purchase Offer for SGX Pharmaceuticals 3Bionovo to Present at BMO Capital Markets 2008 Focus on Healthcare Conference 2Monogram Biosciences Launches First Resistance Assay for HIV Integrase Inhibitors 2Monogram Biosciences Launches First Resistance Assay for HIV Integrase Inhibitors 3Monogram Biosciences Launches First Resistance Assay for HIV Integrase Inhibitors 4Monogram Biosciences Launches First Resistance Assay for HIV Integrase Inhibitors 5
(Date:1/22/2015)... Report Issued by Small Cap IR. In 2011, Nilson Report,s ... at merchants on the leading payment cards rose to $135.3 ... and prepaid cards reached 6.54 billion.  Eight million credit card ... in 2012, and credit and debit card fraud resulted in ...
(Date:1/22/2015)... 22, 2015 Research and Markets ( ... "Global Wearable Technologies Market and Applications, Opportunities, ... and Forecast 2014-2020" report to their offering. ... devices that can be worn on the user,s ...
(Date:1/22/2015)... N.C. , Jan. 22, 2015 Infinisource has launched ... of the G2 model. The G2 sets a higher standard ... iSolved human capital management solution. With plug-and-play installation, touch screen ... time clock provides a robust time collection solution for the ...
Breaking Biology News(10 mins):$4.80 Near Term Price Target with "Buy" given by CapRock Research for NXT-ID, Inc. (NASDAQ: NXTD) issued by Small Cap IR 2Global Wearable Technologies Market and Applications, Opportunities, Industry Analysis, Segmentation, Size, Growth, Share, Overview, Trends and Forecast 2014-2020 2Infinisource's NXG series sets new time clock standard 2
... scientist, has just solved the structure of the first mammalian ... and certain cancers. His work is being published today ... Molecular Cell. Gewirths study confirms his 2001 ... same family as the better known HSP90 proteins. As ...
... Spring Harbor, NY Gregory J. Hannon, Ph.D., ... Hughes Medical Institute (HHMI) investigator, along with two ... the Memorial Sloan-Kettering Cancer Centers (MSKCC) 2007 Paul ... named after Paul A. Marks, Ph.D., President Emeritus ...
... researchers have shown that nanodiamonds -- much like the ... diamond but on a much smaller scale -- are ... the negative effects associated with current drug delivery agents. ... Letters, is the first to demonstrate the use of ...
Cached Biology News:First high-res 3D structures of mammalian HSP90 protein solved 2First high-res 3D structures of mammalian HSP90 protein solved 3Gregory Hannon wins 2007 Paul Marks Prize for contributions to understanding and treating cancer 2Nanoengineers mine tiny diamonds for drug delivery 2Nanoengineers mine tiny diamonds for drug delivery 3Nanoengineers mine tiny diamonds for drug delivery 4
Request Info...
Peptide-affinity Purified Polyclonal Antibody to SMAD7 Peptide with sequence SSCPCWLEVIFNSR, from C Terminus of the protein sequence according to NP_005895....
Polyclonal Antibody to PRG3...
Mouse monoclonal [2991] to C3a / C3a des Arg ( Abpromise for all tested applications). SwissProtID: P01024...
Biology Products: